Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Albert

Podiatrist College Station, TX Doctor of Podiatric Medicine

NPI 1932146206 CMS profile 86921

3312 Longmire Dr, College Station, TX 77845

Open in the dashboard

General payments

$6,624

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Albert of College Station, TX is reported in the CMS Open Payments database as having received $6,624 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,027 16
2024 General $1,212 19
2023 General $1,428 19
2022 General $193 11
2021 General $1,829 12
2020 General $191 9
2019 General $743 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Albert
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Julie Albert were reported at $1,027. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Julie Albert Podiatrist median Middle half National median
2019 $743 $196 $72–$601 $163
2020 $191 $118 $38–$335 $114
2021 $1,829 $169 $57–$573 $132
2022 $193 $220 $74–$782 $149
2023 $1,428 $208 $71–$635 $160
2024 $1,212 $237 $87–$681 $164
2025 $1,027 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paragon 28, Inc. $2,445 8 payments
  2. Treace Medical Concepts, Inc. $1,474 13 payments
  3. Integra LifeSciences Corporation $924 3 payments
  4. Smith+Nephew, Inc. $438 26 payments
  5. Paratek Pharmaceuticals, Inc. $309 15 payments
  6. Medtronic, Inc. $160 2 payments
  7. AxoGen $102 1 payment
  8. Next Science LLC $73 2 payments
  9. Globus Medical, Inc. $70 3 payments
  10. Melinta Therapeutics, Inc. $58 3 payments
  11. Other $573 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,578 97 payments
  2. Travel and Lodging $2,434 6 payments
  3. Long term medical supply or device loan $612 1 payment
Products named General payments · program years 2019–2025
  1. Product Portfolio $1,664 3 payments
  2. LAPIPLASTY SYSTEM Foot And Ankle $937 8 payments
  3. MTP $718 3 payments
  4. AMNIOEXCEL $612 1 payment
  5. Lapiplasty System Y $503 3 payments
  6. Integra Recon-Skin And Wound $313 2 payments
  7. Integra Recon-Skin And Wound $313 2 payments
  8. PRIMATRIX $313 2 payments
  9. Integra Recon-Skin And Wound $313 2 payments
  10. INTEGRA DERMAL REGENERATION TEMPLATE $313 2 payments
  11. Other $2,336 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

480

Median for Podiatry: 160

Drug cost

$6,672

Median for Podiatry: $2,368

Branded share of claims

30.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Terbinafine Hcl Generic 86 $1,902
Diclofenac Sodium Er Diclofenac Sodium Brand 32 $1,215
Cephalexin Generic 77 $828
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 48 $718
Gabapentin Generic 35 $689
Amitriptyline Hcl Generic 101 $655
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 23 $271
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 29 $167
Acetaminophen-Codeine Acetaminophen With Codeine Brand 13 $112
Prednisone Generic 19 $83

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$89,361

Of which drugs: $237

Medicare patients

387

Average age 76

Services billed

2,557

231 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 43%
Ischemic heart disease 34%
Chronic kidney disease 27%
Depression 24%
Atrial fibrillation 21%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 260 $188
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 45 300 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $86
$86 — —
REGRANEX
  • Smith+Nephew, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record